Trials / Conditions / Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors

14 registered clinical trials studyying Pancreatic Neuroendocrine Tumors — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Enrolling By Invitation	Patients With High-grade Pancreatic Neuroendocrine Tumors NCT07121478	National Cancer Center, Korea	Phase 2
Completed	Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China NCT02842749	Novartis Pharmaceuticals	Phase 4
Completed	Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project NCT02685553	Universita di Verona	Phase 1
Completed	Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria NCT02841865	Grupo Espanol de Tumores Neuroendocrinos	—
Completed	The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differen NCT02282059	Pfizer	—
Completed	Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms NCT02125929	Peking Union Medical College Hospital	N/A
Terminated	Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lym NCT02110563	Dicerna Pharmaceuticals, Inc., a Novo Nordisk company	Phase 1
Completed	Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors NCT02586844	University Health Network, Toronto	—
Unknown	Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine T NCT03053999	M.D. Anderson Cancer Center	—
Terminated	Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors NCT01648465	Hellenic Cooperative Oncology Group	Phase 2
Unknown	Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carci NCT01381822	Threshold Pharmaceuticals	Phase 1
Completed	Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal P NCT01384617	Wakayama Medical University	N/A
Completed	Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor NCT01121562	Pfizer	Phase 2
Terminated	A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors NCT00947167	Pamela L. Kunz	Phase 2